Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUGNASDAQ:PVLANASDAQ:RPTXNASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$32.36+2.1%$32.87$0.93▼$79.02$223.30M-5.32821,108 shs15,862 shsPVLAPalvella Therapeutics$21.61-0.4%$24.73$6.20▼$29.27$239.63M0.169,647 shs33,223 shsRPTXRepare Therapeutics$1.33+1.9%$1.16$0.89▼$4.29$57.05M0.85259,279 shs98,300 shsRZLTRezolute$3.56+2.0%$3.24$2.22▼$6.19$215.51M1.01622,041 shs714,164 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+2.08%+0.94%-0.15%-22.58%+2,882.49%PVLAPalvella Therapeutics-0.41%-6.21%-9.69%+10.54%+2,160,999,900.00%RPTXRepare Therapeutics+1.92%-2.21%+20.91%+4.72%-62.75%RZLTRezolute+2.01%-4.30%+35.88%-22.78%+34.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRUGBright Minds Biosciences3.8003 of 5 stars4.64.00.00.03.52.50.0PVLAPalvella Therapeutics4.1635 of 5 stars4.60.00.00.02.74.21.3RPTXRepare Therapeutics3.0154 of 5 stars3.35.00.00.02.02.50.6RZLTRezolute2.71 of 5 stars3.62.00.00.02.64.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 3.25Buy$83.25157.26% UpsidePVLAPalvella Therapeutics 3.13Buy$44.43105.59% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50238.35% UpsideRZLTRezolute 3.14Buy$12.14241.09% UpsideCurrent Analyst Ratings BreakdownLatest RPTX, DRUG, PVLA, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.004/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.004/1/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.003/26/2025PVLAPalvella TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.003/25/2025PVLAPalvella TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/APVLAPalvella Therapeutics$42.81M5.57N/AN/A$21.66 per share1.00RPTXRepare Therapeutics$53.48M1.07N/AN/A$5.03 per share0.26RZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$2.06M-$0.17N/AN/AN/AN/A-5.85%-5.68%5/21/2025 (Estimated)PVLAPalvella Therapeutics-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%N/ARPTXRepare Therapeutics-$93.80M-$2.00N/AN/AN/A-99.76%-40.87%-35.07%N/ARZLTRezolute-$68.46M-$1.22N/AN/AN/AN/A-70.27%-62.41%5/21/2025 (Estimated)Latest RPTX, DRUG, PVLA, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q2 2025DRUGBright Minds Biosciences-$0.38-$0.29+$0.09-$0.29N/AN/A5/21/2025Q3 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A3/3/2025Q4 2024RPTXRepare Therapeutics-$0.77-$0.67+$0.10-$0.67$0.67 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A126.0111.31PVLAPalvella TherapeuticsN/A4.824.82RPTXRepare TherapeuticsN/A6.456.45RZLTRezoluteN/A9.309.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%PVLAPalvella Therapeutics40.11%RPTXRepare Therapeutics85.09%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%PVLAPalvella Therapeutics20.50%RPTXRepare Therapeutics11.50%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionablePVLAPalvella TherapeuticsN/A11.04 million10.50 millionN/ARPTXRepare Therapeutics18042.89 million33.33 millionOptionableRZLTRezolute4060.54 million49.40 millionOptionableRPTX, DRUG, PVLA, and RZLT HeadlinesRecent News About These CompaniesRezolute (RZLT) to Release Earnings on WednesdayMay 16 at 1:45 AM | marketbeat.comRezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia TreatmentMay 16 at 12:07 AM | nasdaq.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 15 at 8:00 AM | marketbeat.comIntegral Health Asset Management LLC Boosts Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)May 14 at 6:18 AM | marketbeat.comJ. Goldman & Co LP Takes $1.14 Million Position in Rezolute, Inc. (NASDAQ:RZLT)May 14 at 5:59 AM | marketbeat.comRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 13 at 4:05 PM | globenewswire.comSchonfeld Strategic Advisors LLC Sells 272,368 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 13 at 3:49 AM | marketbeat.comSusquehanna International Group LLP Buys 788,349 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 7, 2025 | marketbeat.comFDA grants breakthrough status to Rezolute’s hypoglycemia therapyMay 6, 2025 | investing.comRenaissance Technologies LLC Reduces Stake in Rezolute, Inc. (NASDAQ:RZLT)May 6, 2025 | marketbeat.comRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor HyperinsulinismMay 5, 2025 | globenewswire.com683 Capital Management LLC Purchases Shares of 128,668 Rezolute, Inc. (NASDAQ:RZLT)May 4, 2025 | marketbeat.comRezolute to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comRezolute: RZ402 Could Be A Surprise Candidate In The MakingMay 1, 2025 | seekingalpha.comRezolute (NASDAQ:RZLT) Given Buy Rating at HC WainwrightApril 30, 2025 | marketbeat.comNantahala Capital Management LLC Purchases 280,861 Shares of Rezolute, Inc. (NASDAQ:RZLT)April 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Holdings in Rezolute, Inc. (NASDAQ:RZLT)April 30, 2025 | marketbeat.comRezolute Closes $96.9 Million Underwritten OfferingApril 28, 2025 | tipranks.comMarshall Wace LLP Sells 285,409 Shares of Rezolute, Inc. (NASDAQ:RZLT)April 27, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from AnalystsApril 27, 2025 | marketbeat.comMaxim Group Sticks to Its Buy Rating for Rezolute (RZLT)April 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long3 Momentum Stocks That Could Soar Post-Market VolatilityBy Nathan Reiff | April 21, 2025View 3 Momentum Stocks That Could Soar Post-Market VolatilityViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsRPTX, DRUG, PVLA, and RZLT Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$32.36 +0.66 (+2.08%) Closing price 05/15/2025 04:00 PM EasternExtended Trading$34.17 +1.81 (+5.59%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Palvella Therapeutics NASDAQ:PVLA$21.61 -0.09 (-0.41%) As of 05/15/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Repare Therapeutics NASDAQ:RPTX$1.33 +0.03 (+1.92%) Closing price 05/15/2025 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.38%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Rezolute NASDAQ:RZLT$3.56 +0.07 (+2.01%) Closing price 05/15/2025 04:00 PM EasternExtended Trading$3.58 +0.02 (+0.56%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Analysts and Institutions Continue to Bet Big on Alphabet Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
